Case Report and Literature Review of Severe Anemia Secondary to Chemotherapy
Combined with PD-1 Monoclonal Antibody Immunotherapy for Lung Adenocarcinoma.
10.3779/j.issn.1009-3419.2025.102.25
- Author:
Yaowen HU
1
;
Jing ZHAO
2
;
Xiaoxing GAO
2
;
Yan XU
2
;
Mengzhao WANG
2
Author Information
1. Department of Gastroenterology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China.
2. Department of Pulmonary and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China.
- Publication Type:English Abstract
- Keywords:
Anemia;
Immune checkpoint inhibitors;
Immune-related adverse events;
Lung neoplasms;
Programmed cell death 1
- MeSH:
Humans;
Adenocarcinoma of Lung/drug therapy*;
Programmed Cell Death 1 Receptor/antagonists & inhibitors*;
Anemia/etiology*;
Immunotherapy/adverse effects*;
Lung Neoplasms/immunology*;
Male;
Antibodies, Monoclonal/therapeutic use*;
Middle Aged
- From:
Chinese Journal of Lung Cancer
2025;28(6):472-476
- CountryChina
- Language:Chinese
-
Abstract:
Programmed cell death 1 (PD-1) inhibitor therapy for lung adenocarcinoma may induce rare but severe hematologic adverse events, including severe anemia. Although glucocorticoids are recommended for managing immune-related adverse events, therapeutic experience with PD-1 inhibitor-induced severe anemia remains limited, and its efficacy and safety have not been fully validated. This article reports a case of advanced lung adenocarcinoma in which severe anemia developed following combination therapy with chemotherapy and PD-1 inhibitor. After comprehensive evaluation, the patient was diagnosed with anemia of inflammation (AI) and achieved significant hemoglobin recovery following high-dose glucocorticoid treatment. These findings may provide new insights into the recognition and management of this rare hematologic toxicity in clinical practice.
.
